South America Blood Transfusion Diagnostics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Product, Application, and End User

The SAM blood transfusion diagnostics market is expected to grow from US$ 217.55 million in 2022 to US$ 302.89 million by 2028. It is estimated to grow at a CAGR of 5.7% from 2022 to 2028.

Blood Transfusion Diagnostics are usually deployed during long-hour surgeries, such as kidney transplants, and in cases of emergencies. These surgeries are associated with the chances of excessive blood loss, which makes it difficult to make up for the blood loss with new blood, especially in the case of rare blood groups. Due to the ample demand, key players in the blood transfusion diagnostics market offer advanced and fully automated blood transfusion diagnostics that reduce human interventions. For instance, in April 2019, BD launched its BD BACTEC quality control media to help identify contaminated platelet units during transfusions. Moreover, many companies employed strategic activities, such as acquisitions, partnerships, and other activities, to capture the market. For instance, in December 2019, Getinge purchased Applikon Biotechnology, a leader in the development and supply of innovative bioreactor systems from the laboratory to the industrial scale. In October 2019, Medtronic acquired AV Medical Technologies. Thus, such advancements are likely to bring new trends in the blood transfusion diagnostics market in the coming years.

Market Overview

Brazil is one of the largest countries in SAM. It has a well-established medical device industry regulated by the Brazilian National Health Surveillance Agency (ANVISA). Similarly, the National Institute of Metrology Standardization and Industrial Quality (INMETRO) sets the standards and guidance for companies in the medical device industry in the country. Brazil has the most significant medical equipment industry in the region and is the largest importer of medical devices for the US as it imports ~30% of medical devices from the US. Moreover, sepsis is a severe health issue in Brazil, and this condition requires blood transfusion as a line of treatment. A study published on SciELO from Brazil in 2022 demonstrated that sepsis prevalence is 30% in Brazilian ICUs, while the hospital mortality rate for ICU patients is 55%. Reasons for the significant burden of sepsis include inadequacy of clean water, sanitation, and nutrition; insufficiency of vaccination; low access to intensive care services; and increased incidence of healthcare-associated infections. Therefore, the growing prevalence of sepsis is one of the factors contributing to the blood transfusion diagnostics market growth in Brazil. Furthermore, according to the Brazilian Ministry of Health, 1.9% of the Brazilian population donates blood yearly, accounting for ~4 million blood donations. In Brazil, ~3 million units of blood are collected each year, with the public system accounting for ~70% of donations in these areas. Thus, the abovementioned factors propel the demand for blood transfusion diagnostics in Brazil.

SAM Blood Transfusion Diagnostics Market Segmentation

The SAM blood transfusion diagnostics market is segmented based on product, application, end user, and country.

• Based on product, the SAM blood transfusion diagnostics market is bifurcated into instruments & kits and reagents. The instruments & kits segment held the larger market share in 2022.
• Based on application, the SAM blood transfusion diagnostics market is bifurcated into blood grouping and disease screening. The disease screening segment held the larger market share in 2022.
• Based on end user, the SAM blood transfusion diagnostics market is segmented into hospitals, diagnostic laboratories, blood banks, and plasma fractionation companies. The blood banks segment dominated the market in 2022.
• Based on country, SAM blood transfusion diagnostics market has been categorized into Brazil, Argentina, and Rest of SAM. Our regional analysis states that Brazil dominated the market in 2022. Abbott; BAG Diagnostics GmbH; Bio-Rad Laboratories, Inc.; DiaSorin S.p.A.; F. Hoffmann-La Roche Ltd; Grifols, S.A.; Immucor, Inc.; Ortho Clinical Diagnostics (QuidelOrtho Corporation); Quotient Limited; and Thermo Fisher Scientific Inc. are the leading companies operating in the SAM blood transfusion diagnostics market.